Gastresophagel cancer incidence has increased up to 400%. The introduction of preoperative chemotherapy and first targeted therapies in the treatment of gastroesophageal cancer has influenced prognosis.
Biliary Tract Cancer
Cancer of the biliary tract is the second most common type of cancer to involve the region of the liver. Clinical research are challenging better diagnosis and multimodal tretament concepts.
Many colon cancer treatment options are available for colorectal cancer, including surgery, chemotherapy, and radiation. The optimal sequence will influence patient´s outcome.
The prognosis of pancreatic cancer is still poor. Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy will be in the focus.
GIST is the most common mesenchymal neoplasm of the gastrointestinal tract. Tyrosinkinase inhibitors have been proven in adjuvant or neoadjuvant but also in recurrent stage of disease.
HCC is currently one of the most common worldwide causes of cancer death, In creating a treatment plan, important factors to consider include function stage
Factors that determine the clinical course and outcome of patients with GI-NETs are complex. For optimal treatment the input of multiple specialists is inquired.
Bariatric surgery has been proven as an effective and durable tool in fighting obesity with a dramatic impact on diabetes, hyperlipidemia, hypertension and sleep apnea.
New developments and promising laboratory discoveries for future treatments of cancer patients.
Our Top Speakers on IASGO 2014
|Philippe Bachellier||France||Extended pancreatic resection combined with en-bloc arterial and venous resections for locally advanced cancer: who are best candidates ?|
Algorithm for management of patients affected by HCC suitable for curative treatments: Liver Transplantation or Liver Resection?
|Dave Dietz||USA||Improving U.S. Rectal Cancer Care: the OSTRICH initiative|
|Ho-Seong Han||Korea||Current Status of Laparoscopic Liver Resection|
|Norihiro Kokudo||Japan||How can liver surgeons contribute to the development of treatment algorithms for hepatocellular carcinoma?|
|Nikolaos Lygidakis||Greece||Conflicts & dilemmas of pancreatic surgery for pancreatic cancer: the challenge of radical resection|
|Masatoshi Makuuchi||Japan||Hilar Cholangiocarcinoma－Standard Surgical Procedure|
|Satoru Murata||Japan||Interventional management for advanced liver and pancreatic malignancies: percutaneous isolated perfusion therapies|
|Akimasa Nakao||Japan||How to prevent gastric congestion after superior mesenteric vein-portal vein confluence resection without splenic vein reconstruction in pancreatoduodenectomy|
|Pascal Piedbois||France||Anticancer drugs for tomorrow: What big pharma have in their pipes|
|Yasuyuki Seto||Japan||Treatment Strategy for Esophago-Gastric Junction Cancer|
|Olivier Soubrane||France||Laparoscopic liver surgery: state-of-the art|
|Chris Wolfgang||USA||Genetics, biology and surgery for IPMN|
|Anusak Yiengpruksawan||USA||Is radical pancreatectomy possible with Robotic approach?|